Personalized treatment for depression using mobile technology
SCH: Personalized Depression Treatment Supported by Mobile Sensor Analytics
NA · UConn Health · NCT06292221
This study is testing a new mobile system that helps doctors track and understand depression symptoms in patients to provide better personalized treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Sex | All |
| Sponsor | UConn Health (other) |
| Locations | 1 site (Farmington, Connecticut) |
| Trial ID | NCT06292221 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and evaluate a digital system called DepWatch, which utilizes mobile health technologies and machine learning to monitor and assess depression symptoms in patients. By passively collecting data from smartphones and wristbands, the system provides clinicians with timely and objective insights into patient symptom levels and treatment responses. The collected data includes ecological momentary assessments and medication adherence information, which are analyzed to predict treatment trajectories and inform clinical decision-making.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are experiencing moderate depression and are starting or adjusting their pharmacological treatment.
Not a fit: Patients with primary psychotic disorders, active substance use disorders, or significant cognitive deficits may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for individuals suffering from depression.
How similar studies have performed: While the use of mobile health technologies in mental health treatment is gaining traction, this specific approach utilizing machine learning for personalized depression treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 year or older * Moderate level of depression as defined by a score of ≥ 11 on the 16 item Quick Inventory of Depressive Symptomatology (QIDS) self-report questionnaire * Initiating a pharmacological treatment for depression as monotherapy or adjunctive treatment or reporting a dose increase with their existing depression treatment. Exclusion Criteria: * Diagnosis of a primary psychotic disorder such as schizophrenia or schizoaffective disorder * Currently active substance use disorder (within 1 month of enrollment) dominating clinical scenario * Other clinically significant medical of psychiatric conditions that may adversely affect participants' study participation and/or affect their adherence to study protocol (as determined by study clinician) e.g., significant cognitive deficits
Where this trial is running
Farmington, Connecticut
- University of Connecticut Health Center — Farmington, Connecticut, United States (RECRUITING)
Study contacts
- Principal investigator: Jayesh Kamath, MD PhD — UConn Health
- Study coordinator: Galina Prpich, MS
- Email: prpich@uchc.edu
- Phone: 8606797539
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Depression, smartphone